Puma Biotechnology, Inc.
(NASDAQ : PBYI)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -3.63%62.610.0%$958.21m
NVAXNovavax, Inc. -2.02%94.36251.8%$764.51m
AMGNAmgen, Inc. -1.04%249.041.3%$693.79m
REGNRegeneron Pharmaceuticals, Inc. -3.09%620.862.5%$663.02m
GILDGilead Sciences, Inc. 2.16%76.321.0%$630.80m
BIIBBiogen, Inc. 0.07%278.881.6%$601.57m
VRTXVertex Pharmaceuticals, Inc. -0.32%294.451.9%$475.52m
ILMNIllumina, Inc. -0.63%370.253.5%$301.18m
VXRTVaxart, Inc. -2.56%7.980.0%$286.91m
ALXNAlexion Pharmaceuticals, Inc. 0.32%108.822.0%$217.19m
BMRNBioMarin Pharmaceutical, Inc. -0.59%126.064.3%$206.81m
SRNESorrento Therapeutics, Inc. 4.00%8.061.8%$192.86m
SGENSeattle Genetics, Inc. -3.76%174.356.1%$192.39m
IMMUImmunomedics, Inc. -2.32%41.3211.0%$177.00m
ALNYAlnylam Pharmaceuticals, Inc. 2.03%162.258.5%$166.65m

Company Profile

Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.